Shin Takahashi

Profile Information

Affiliation: Graduate Student, Tohoku University

Degree: 医学博士(東北大学大学院)

J-GLOBAL ID: 200901076156482930
researchmap Member ID: 5000066963

Research Interests

Research Areas

Education

Apr, 1999 - Mar, 2005

医学研究科, 東北大学大学院

Awards

Apr, 2015

奨励賞, 日本内科学会

高橋信
Jul, 2014

奨励賞, 日本臨床腫瘍学会

高橋信

Papers

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.

Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H …

International journal of clinical oncology, 23(4) 790-798, Aug, 2018 Peer-reviewed
Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey.

Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M …

Japanese journal of clinical oncology, 48(10) 913-919, Aug, 2018 Peer-reviewed
Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.

Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y …

The Tohoku journal of experimental medicine, 245(2) 123-129, Jun, 2018 Peer-reviewed
Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.

Akira Okita, Shin Takahashi, Kota Ouchi, Masahiro Inoue, Mika Watanabe, Mareyuki Endo, Hiroshi Honda, Yasuhide Yamada, Chikashi Ishioka

Oncotarget, 9(27) 18698-18711, Apr 10, 2018 Peer-reviewed
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): A randomized, open-label, phase III, noninferiority trial

Y. Yamada, T. Denda, M. Gamoh, I. Iwanaga, S. Yuki, H. Shimodaira, M. Nakamura, T. Yamaguchi, H. Ohori, K. Kobayashi …

Annals of Oncology, 29(3) 624-631, Mar 1, 2018 Peer-reviewed
Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer

Shigeo Yamaguchi, Shin Takahashi, Kaoru Mogushi, Yuki Izumi, Yumi Nozaki, Tadashi Nomizu, Yoichiro Kakugawa, Takanori Ishida, Noriaki Ohuchi, Chikashi Ishioka …

Oncotarget, 9(18) 14193-14206, 2018 Peer-reviewed
microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer

Hidekazu Takahashi, Masanobu Takahashi, Shinobu Ohnuma, Michiaki Unno, Yuki Yoshino, Kota Ouchi, Shin Takahashi, Yasuhide Yamada, Hideki Shimodaira, Chikashi Ishioka

BMC CANCER, 17(1) 723, Nov, 2017 Peer-reviewed
The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study

Masahiro Takahashi, Masanobu Takahashi, Keigo Komine, Hideharu Yamada, Yuki Kasahara, Sonoko Chikamatsu, Akira Okita, Shukuei Ito, Kota Ouchi, Yoshinari Okada …

PLOS ONE, 12(6) e0179694, Jun, 2017 Peer-reviewed
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

Masanobu Takahashi, Keigo Komine, Hiroo Imai, Yoshinari Okada, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Hisatsugu Ohori, Shin Takahashi, Natsuko Chiba …

PLOS ONE, 12(5) e0176972, May, 2017 Peer-reviewed
Current situation regarding central venous port implantation procedures and complications: a questionnaire-based survey of 11,693 implantations in Japan

Masatoshi Shiono, Shin Takahashi, Masanobu Takahashi, Takuhiro Yamaguchi, Chikashi Ishioka

International Journal of Clinical Oncology, 21(6) 1172-1182, Dec, 2016 Peer-reviewed
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer

Xiaofei Zhang, Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Hidekazu Takahashi, Kota Ouchi, Masahiro Inoue, Masanobu Takahashi, Shin Takahashi, Chikashi Ishioka

International Journal of Clinical Oncology, 21(6) 1091-1101, Dec, 2016 Peer-reviewed
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease

Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota …

INTERNAL MEDICINE, 55(6) 629-634, 2016 Peer-reviewed
Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer

Masahiro Inoue, Shin Takahashi, Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe, Koh Miura, Iwao Sasaki, Shunsuke Kato, Chikashi Ishioka

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20(6) 1147-1155, Dec, 2015 Peer-reviewed
DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H …

Cancer science, 106(12) 1722-1729, Dec, 2015 Peer-reviewed
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

Yoshito Komatsu, Chikashi Ishioka, Ken Shimada, Yasuhide Yamada, Makio Gamoh, Atsushi Sato, Tatsuro Yamaguchi, Satoshi Yuki, Satoshi Morita, Shin Takahashi …

BMC CANCER, 15 626, Sep, 2015 Peer-reviewed
Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status An Independent Prognostic Factor of Breast Cancer

Gou Watanabe, Takanori Ishida, Akihiko Furuta, Shin Takahashi, Mika Watanabe, Hideaki Nakata, Shunsuke Kato, Chikashi Ishioka, Noriaki Ohuchi

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 39(8) 1026-1034, Aug, 2015 Peer-reviewed
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

S. Ohkawa, T. Okusaka, H. Isayama, A. Fukutomi, K. Yamaguchi, M. Ikeda, A. Funakoshi, M. Nagase, Y. Hamamoto, S. Nakamori …

BRITISH JOURNAL OF CANCER, 112(9) 1428-1434, Apr, 2015 Peer-reviewed
Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series

Hiroo Imai, Hidekazu Shirota, Akira Okita, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

CHEMOTHERAPY, 61(3) 111-116, 2015 Peer-reviewed
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Hiroo Imai, Keigo Komine, Shin Takahashi, Ken Saijo, Yoshinari Okada, Akihiro Kobayashi, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Masahiro Takahashi …

CHEMOTHERAPY, 61(5) 262-268, 2015 Peer-reviewed
Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion

Masatoshi Shiono, Shin Takahashi, Yuichi Kakudo, Masanobu Takahashi, Hideki Shimodaira, Shunsuke Kato, Chikashi Ishioka

PLOS ONE, 9(3) e91335, Mar, 2014 Peer-reviewed

Presentations

DNA メチル化状態は進行再発大腸癌に対する抗EGFR 抗体薬の治療効果予測性において原発巣の左右差より優れる

大内康太, 沖田啓, 高橋信, 石岡千加史

第 16 回日本臨床腫瘍学会学術集会, Jul 21, 2018
早期乳がん予後予測バイオマーカーTP53 signature

高橋信

第26回日本乳癌学会学術総会, May 16, 2018 Invited
The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer

Okita, A, Takahashi, S, Ouchi, K, Inoue, M, Yamada, Y, Ishioka, C

2018 Gastrointestinal Cancers Symposium, Jan 20, 2018
Consensus Molecular Subtypes（CMS）は抗EGFR抗体薬の治療効果予測因子となる

沖田啓, 高橋信, 大内康太, 山田康秀, 高橋雅信, 石岡千加史

第76回日本癌学会学術総会, Sep 29, 2017
Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer

TAKAHASHI Shin

ESMO2018, Sep 11, 2017
Consensus molecular subtypes（CMS）に基づく、進行・再発大腸癌に対する最適な化学療法の検討

沖田啓, 高橋信, 大内康太, 山田英晴, 笠原佑記, 近松園子, 高橋秀和, 高橋雅信, 下平秀樹, 石岡千加史

第15回日本臨床腫瘍学会学術集会, Jul 29, 2017
Development of in vitro diagnostics for TP53 signature aiming at optimization of breast cancer treatment

TAKAHASHI Shin

Jul 28, 2017
Development of TP53 signature using multiplex RT-PCR method to predict the prognosis of breast cancer patients

TAKAHASHI Shin

Jul 13, 2017
The prediction of prognosis and chemosensitivity by TP53 signature in breast cancer

TAKAHASHI Shin

20th Breast Cancer UP-TO-DATE Meeting, Mar 11, 2017
大腸がん治療におけるエピジェネティックバイオマーカー

高橋信

第75回日本癌学会学術総会, Oct 6, 2016 Invited
Developing biomarker of early stage breast cancer using expression profile of TP53 mutation status

TAKAHASHI Shin

Jul 29, 2016

Professional Memberships

Research Projects

癌の分子診断

2001
Molecular diagnosis of cancer

2001

Profile Information

Research Interests

Research Areas

Education

Awards

Papers

Presentations

Professional Memberships

Research Projects

Industrial Property Rights

Menu